Asset Details
Do you wish to reserve the book?
KANK1‐ALK, a rare ALK fusion in mucinous lung adenocarcinoma with primary resistance to ALK‐TKI treatment: A case report
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
KANK1‐ALK, a rare ALK fusion in mucinous lung adenocarcinoma with primary resistance to ALK‐TKI treatment: A case report
Do you wish to request the book?
KANK1‐ALK, a rare ALK fusion in mucinous lung adenocarcinoma with primary resistance to ALK‐TKI treatment: A case report
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
KANK1‐ALK, a rare ALK fusion in mucinous lung adenocarcinoma with primary resistance to ALK‐TKI treatment: A case report
2025
Overview
Patients harboring rearrangements of anaplastic lymphoma kinase (ALK) fusion may respond differently to ALK tyrosine kinase inhibitors (TKIs) depending on changes in the type of ALK rearrangements. We report the first documented case of KANK1‐ALK fusion in mucinous lung adenocarcinoma, co‐occurring with TP53 mutation. The patient underwent targeted therapy with loratinib and iruplinalkib, followed by alternative chemotherapy. Unfortunately, the KANK1‐ALK fusion in this patient exhibited resistance to all the existing ALK‐TKIs, and the patient's condition has worsened repeatedly. Uncommon ALK fusion patterns present substantial therapeutic obstacles in clinical practice. Accurate detection of ALK fusion types is of great significance in formulating precise treatment plans. An increasing number of clinical specimens have detected rare fusions, and the treatment of rare fusions may be a research direction in the future.
Publisher
John Wiley & Sons Australia, Ltd,John Wiley & Sons, Inc,Wiley
Subject
We currently cannot retrieve any items related to this title. Kindly check back at a later time.